Send to

Choose Destination
Eur Urol. 2010 Aug;58(2):311-2.

Words of wisdom. Re: Phase 1 trial of high-dose exogenous testosterone in patients with castration-resistant metastatic prostate cancer. Morris MJ, Huang D, Kelly WK, et al. Eur Urol 2009;56:237-44.

Author information

Department of Urology, University of Washington, Seattle, Washington, USA.


Laboratory studies suggest that castration-resistant prostate cancer (CRPC) cell growth is suppressed by supraphysiologic doses of testosterone (T). In this study, 12 men received high doses of T transdermally for 7 d, for 4 mo, or until progression.The approach was safe and toxicity was mild, but responses were modest. Because serum T did not reach intended supraphysiologic levels, the authors urged more clinical testing.


Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center